HLS Therapeutics (TSE:HLS) Hits New 1-Year High - What's Next?

Key Points

• HLS Therapeutics Inc. shares reached a new 52-week high of C$5.48 during trading, closing at C$5.10.
• The company has a market capitalization of C$114.80 million and a price-to-earnings ratio of -5.17.
• HLS Therapeutics specializes in the acquisition and commercialization of branded pharmaceutical products, particularly for central nervous system and cardiovascular treatments.

HLS Therapeutics Inc. (TSE:HLS - ) shares hit a new 52-week high during trading on Tuesday . The stock traded as high as C$5.48 and last traded at C$5.10, with a volume of 4686 shares traded. The stock had previously closed at C$5.16.

HLS Therapeutics Stock Performance

The company has a debt-to-equity ratio of 86.50, a quick ratio of 1.01 and a current ratio of 1.56. The stock has a market capitalization of C$114.80 million, a price-to-earnings ratio of -5.17 and a beta of 1.07. The stock has a fifty day simple moving average of C$4.94 and a two-hundred day simple moving average of C$4.58.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.